Literature DB >> 14660014

Systemic galnon, a low-molecular weight galanin receptor agonist, reduces heat hyperalgesia in rats with nerve injury.

Wei-Ping Wu1, Jing-Xia Hao, Linda Lundström, Zsuzsanna Wiesenfeld-Hallin, Ulo Langel, Tamas Bartfai, Xiao-Jun Xu.   

Abstract

We have examined the effect of systemically administered galnon, a novel low-molecular weight agonist of galanin receptors, on neuropathic pain-like behaviors in rats after photochemically induced partial nerve injury. Galnon is a galanin receptor ligand with moderate affinity to spinal cord membranes (K(D) of 6+/-0.6 microM). While intraperitoneally applied galnon produced no significant effect on mechanical or cold hypersensitivity, it dose-dependently prolonged heat withdrawal latency in nerve-injured rats. The effect of galnon was more potent on the injured side which has significantly shorter latency than the contralateral side. The anti-hyperalgesic effect of galanon was prevented by intrathecal M35, a galanin receptor antagonist. No side effects, such as sedation or motor impairment, were seen following systemic galnon treatment at the doses used. It is concluded that systemic galnon alleviated heat-hyperalgesic response in rats with partial sciatic nerve injury. This effect was likely to be mediated by activation of spinal galanin receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660014     DOI: 10.1016/j.ejphar.2003.09.018

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests.

Authors:  Tamas Bartfai; Xiaoying Lu; Hedieh Badie-Mahdavi; Alasdair M Barr; Andrey Mazarati; Xiao-Ying Hua; Tony Yaksh; Gebhard Haberhauer; Susana Conde Ceide; Laurent Trembleau; Laszlo Somogyi; Lenz Kröck; Julius Rebek
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

2.  Locomotion and self-administration induced by cocaine in 129/OlaHsd mice lacking galanin.

Authors:  Christian Brabant; Anna S Kuschpel; Marina R Picciotto
Journal:  Behav Neurosci       Date:  2010-12       Impact factor: 1.912

3.  Phenotypic analysis of mice deficient in the type 2 galanin receptor (GALR2).

Authors:  Michelle L Gottsch; Hongkui Zeng; John G Hohmann; David Weinshenker; Donald K Clifton; Robert A Steiner
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

4.  Galanin protects against behavioral and neurochemical correlates of opiate reward.

Authors:  Jessica J Hawes; Darlene H Brunzell; Roopashree Narasimhaiah; Ulo Langel; David Wynick; Marina R Picciotto
Journal:  Neuropsychopharmacology       Date:  2007-10-24       Impact factor: 7.853

5.  Effects of galanin on cocaine-mediated conditioned place preference and ERK signaling in mice.

Authors:  Roopashree Narasimhaiah; Helen M Kamens; Marina R Picciotto
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

6.  The galanin receptor agonist, galnon, attenuates cocaine-induced reinstatement and dopamine overflow in the frontal cortex.

Authors:  Yvonne E Ogbonmwan; Natale R Sciolino; Jessica L Groves-Chapman; Kimberly G Freeman; Jason P Schroeder; Gaylen L Edwards; Philip V Holmes; David Weinshenker
Journal:  Addict Biol       Date:  2014-07-23       Impact factor: 4.280

7.  Homology modeling, docking, and molecular dynamics simulation of the receptor GALR2 and its interactions with galanin and a positive allosteric modulator.

Authors:  Wen-Qi Hui; Qi Cheng; Tian-Yu Liu; Qin Ouyang
Journal:  J Mol Model       Date:  2016-03-28       Impact factor: 1.810

8.  Galanin receptors and ligands.

Authors:  Kristin E B Webling; Johan Runesson; Tamas Bartfai; Ulo Langel
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-07       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.